# Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

> **NCT04472494** · PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 61 (actual)

## Conditions studied

- COVID-19
- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** Abatacept
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04472494
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-14
- **Primary completion:** 2021-08-12
- **Final completion:** 2021-09-13
- **Target enrollment:** 61 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2022-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04472494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04472494, "Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04472494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*